HSTO - Histogen Amerimmune inks emricasan agreement for COVID-19

Histogen (HSTO) ticks 2% higher in premarket on light volume after announcing an agreement with Amerimmune to jointly develop emricasan a caspase inhibitor, for the treatment of COVID-19.Additionally, the FDA has signed-off Phase 1 study of emricasan in mild-COVID-19 patients to assess safety and tolerability.Amerimmune will lead the development efforts of emricasan and anticipates initiating the Phase 1 study as early as the end of this year.Under the terms of the collaboration, Histogen will retain ownership over emricasan and responsibility for all regulatory filings. Amerimmune will fund and lead the emricasan development efforts and maintain its own portfolio of patents for caspase inhibition and immunotherapy.Additionally, Amerimmune has been granted an option to commercialize emricasan under certain conditions for the sole purpose of supporting future third-party partnering transactions. Should any such partnering transaction emerge, Histogen and Amerimmune will share profits equally.

For further details see:

Histogen, Amerimmune inks emricasan agreement for COVID-19